Oncology testing includes assays for fusion gene/transcript detection and quantitation. The laboratory performed about 2,000 molecular tests a year with the continual addition of new tests and participates in collaborative research with the aim of developing molecular tests for clinical applications. Our primary focus is to provide high complexity, cancer and non cancer -related laboratory testing services to hospitals, community-based pathology practices, and clinicians throughout the United States. We currently perform analyses for hematopoietic cancers such as leukemia and lymphoma (blood and lymphoid tumors) and solid tumor cancers such as breast, lung, colon, and bladder cancer. For hematopoietic cancers, we typically analyze bone marrow aspirate and peripheral blood specimens. For solid tumor cancers, we typically analyze tissue samples or urine.Both qualitative and quantitative molecular testing is offered utilizing PCR, RT- PCR, multiplex PCR, real time PCR and Nextgen sequencing methods. Our mission is to develop genetic tests that will become the model for comprehensive disease detection and informed treatment, ushering in a new era of predictive, preventative and affordable health care. Our laboratory is CLIA certified (Clinical Laboratory Improvement Amendment).